Titre:
  • Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
Auteur:Collet, L; Noël, J-C; Catteau, Xavier; Ardin, Maude; Berthet, Justine; Ghamry-Barrin, Sarah; Treilleux, I; Bengrine Lefevre, Leïla; Martinez, M; Rothé, Françoise; Sotiriou, Christos; Caux, C; Dubois, B; Ray-Coquard, Isabelle; Le Saux, Olivia
Informations sur la publication:ESMO Open, 10, 6, page (105104)
Statut de publication:Publié, 2025-06-01
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:high-grade serous ovarian cancer
immunotherapy
platinum-based chemotherapy
tumor microenvironment
tumor–stroma proportion
MeSH keywords:Humans
Female
Ovarian Neoplasms -- pathology -- drug therapy -- mortality
Prognosis
Middle Aged
Aged
Biomarkers, Tumor
Antibodies, Monoclonal, Humanized -- therapeutic use
Immunotherapy -- methods
Tumor Microenvironment
Adult
Stromal Cells -- pathology
Immune Checkpoint Inhibitors -- therapeutic use
Langue:Anglais
Identificateurs:urn:issn:2059-7029
info:doi/10.1016/j.esmoop.2025.105104
info:pii/S2059-7029(25)00973-1
info:pmid/40472658
PMC12172955